바이오비쥬

489460KOSDAQ기타 화학제품 제조업

54.5 / 100

Reference Date: 2026-04-13

Financial Score22.0 / 40

News Sentiment17.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Declined 7.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BioViju is a global export-focused company specializing in the research, development, and manufacturing of hyaluronic acid (HA)-based skin boosters and fillers, utilizing cross-linking and LNP technologies to ensure product safety. With its own production facility and ISO certification, the company is expanding OEM and general distribution, aiming to secure growth momentum through the expansion of HA filler approvals both domestically and internationally.

Number of Employees

51people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

29.87Industry Average 18.381.5Point

1.6x industry avg (risky)

PBR

2.16Industry Average 1.371.0Point

1.6x industry avg (risky)

ROE

8.94Industry Average 4.555.5Point

2.0x industry avg (good)

Debt Ratio

0.31Industry Average 8.138.0Point

Half of industry avg (excellent)

Trend 6.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

3.0 / 4

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 70

Positive
바이오비쥬, 피부미용 필러 '코레나' 품목허가 획득
바이오비쥬는 피부미용 필러 제품 '코레나'의 국내 품목허가를 획득하며 제품 라인업을 강화했습니다.
Positive
바이오비쥬, 상장 첫해 영업익 반토막…"ECM 스킨부스터 집중"
바이오비쥬는 상장 첫해 영업이익이 감소했으나, ECM 스킨부스터 신제품 '셀리비온'에 집중하여 실적 성장의 토대를 마련할 계획입니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 8,900Won52-week high 22,45052-week low 7,800

1-month return1.0Point

1m -7.48% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral정기주주총회결과2026-03-31
Neutral사업보고서 (2025.12)2026-03-23
Neutral감사보고서제출2026-03-23
Neutral주주총회소집공고2026-03-16